Dr. Furie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
865 Northern Boulevard
Suite 302
Great Neck, NY 11021Phone+1 516-708-2550Fax+1 516-708-2597
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Rheumatology, 1982 - 1984- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1979 - 1982
Weill Cornell MedicineClass of 1979
Certifications & Licensure
NY State Medical License 1980 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Newsday - Top Doctors on Long Island Castle Connolly, 2010-2014
- Top Doctors: New York Metro Area Castle Connolly, 2002-2014
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013
- Join now to see all
Publications & Presentations
PubMed
- Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.Richard A Furie, Brad H Rovin, Jay P Garg, Mittermayer B Santiago, Gustavo Aroca-Martínez
The New England Journal of Medicine. 2025-02-07 - 3 citationsSuccessful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders.Dimitrios Mougiakakos, Ranjita Sengupta, Ralf Gold, Roland Schroers, Aiden Haghikia
Cytotherapy. 2025-02-01 - Reduced organ damage accumulation in adult patients with SLE on anifrolumab plus standard of care compared to real-world external controls.Zahi Touma, Ian N Bruce, Richard Furie, Eric Morand, Raj Tummala
Annals of the Rheumatic Diseases. 2025-02-01
Journal Articles
- Two-Year, Randomized, Controlled Trial of Belimumab in Lupus NephritisRichard Furie, Brad H Rovin, The New England Journal of Medicine
Lectures
- 6th Annual Perspectives in Rheumatic DiseasesGlobal Academy for Medical Education (Elsevier), Las Vegas, Nevada - 9/20/2013
- Advances in B Cell Biology: Rheumatoid Arthritis, Systemic Lupus Erythematosus, & VasculitisCleveland Clinic - Cleveland, Ohio / The Cleveland Clinic Foundation, Scottsdale, Arizona - 2/18/2012
Press Mentions
Obinutuzumab Efficacious for Renal Response in Lupus NephritisFebruary 26th, 2025- Genentech’s Monoclonal Antibody for Active Lupus Nephritis Excels in Phase IIIFebruary 12th, 2025
- Obinutuzumab for Lupus Nephritis Boosts Complete RemissionsFebruary 7th, 2025
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
